Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Gene Microarray Assessment of Multiple Genes and Signal Pathways Involved in Androgen-dependent Prostate Cancer Becoming Androgen Independent

  • Liu, Jun-Bao (China-Japan Union Hospital of Jilin University) ;
  • Dai, Chun-Mei (Changchun Central Hospital) ;
  • Su, Xiao-Yun (College of Pharmacy, Jilin University) ;
  • Cao, Lu (China-Japan Union Hospital of Jilin University) ;
  • Qin, Rui (China-Japan Union Hospital of Jilin University) ;
  • Kong, Qing-Bo (China-Japan Union Hospital of Jilin University)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

To study the gene expression change and possible signal pathway during androgen-dependent prostate cancer (ADPC) becoming androgen-independent prostate cancer (AIPC), an LNCaP cell model of AIPC was established using flutamide in combination with androgen-free environment inducement, and differential expression genes were screened by microarray. Then the biological process, molecular function and KEGG pathway of differential expression genes are analyzed by Molecule Annotation System (MAS). By comparison of 12,207 expression genes, 347 expression genes were acquired, of which 156 were up-ragulated and 191 down-regulated. After analyzing the biological process and molecule function of differential expression genes, these genes are found to play crucial roles in cell proliferation, differntiation, cell cycle control, protein metabolism and modification and other biological process, serve as signal molecules, enzymes, peptide hormones, cytokines, cytoskeletal proteins and adhesion molecules. The analysis of KEGG show that the relevant genes of AIPC transformation participate in glutathione metabolism, cell cycle, P53 signal pathway, cytochrome P450 metabolism, Hedgehog signal pathway, MAPK signal pathway, adipocytokines signal pathway, PPAR signal pathway, TGF-${\beta}$ signal pathway and JAK-STAT signal pathway. In conclusion, during the process of ADPC becoming AIPC, it is not only one specific gene or pathway, but multiple genes and pathways that change. The findings above lay the foundation for study of AIPC mechanism and development of AIPC targeting drugs.

Keywords

References

  1. Cariaga-Martinez AE, Lopez-Ruiz P, Nombela-Blanco MP, et al (2013). Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells. Cell Signal, 25, 1586-97. https://doi.org/10.1016/j.cellsig.2013.03.019
  2. Carstens JL, Shahi P, Van Tsang S, et al (2014). FGFR1- WNT-TGF-$\beta$ signaling in prostate cancer mouse models recapitulates human reactive Stroma. Cancer Res, 74, 609-20. https://doi.org/10.1158/0008-5472.CAN-13-1093
  3. Dreicer R (2014). How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. Can J Urol, 21, 93-7.
  4. He M, Liu Y, Deng X, et al (2013). Down-regulation of miR-200b-3p by low p73 contributes to the androgenindependence of prostate cancer cells. Prostate, 73, 1048-56. https://doi.org/10.1002/pros.22652
  5. Heidenreich A, Bastian PJ, Bellmunt J, et al (2014). EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol, 65, 467-79. https://doi.org/10.1016/j.eururo.2013.11.002
  6. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  7. Kahn B, Collazo J, Kyprianou N (2014). Androgen receptor as a driver of therapeutic resistance in advancedprostate cancer. Int J Biol Sci, 10, 588-95. https://doi.org/10.7150/ijbs.8671
  8. Mukherji D, Pezaro CJ, Shamseddine A, et al (2013). New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat Rev, 39, 578-83. https://doi.org/10.1016/j.ctrv.2012.12.004
  9. Nemes A , Tomuleasa C, Kacso G (2014). The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments. J BUON, 19, 357-64.
  10. Nyquist MD, Li Y, Hwang TH, et al (2013). TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci USA, 110, 17492-7. https://doi.org/10.1073/pnas.1308587110
  11. Shi X, Gipp J, Dries M, et al (2014). Prostate progenitor cells proliferate in response to castration. Stem Cell Res, 13, 154-63. https://doi.org/10.1016/j.scr.2014.04.005
  12. Sooriakumaran P, Nyberg T, Akre O, et al (2014). Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. Brit Med J, 348, 1502. https://doi.org/10.1136/bmj.g1502
  13. Wang X-Y, Hao J-W, Zhou R-J, et al (2013). Meta-analysis of gene expression data identifies causal genes for prostate cancer. Asian Pac J Cancer Prev, 14, 457-61. https://doi.org/10.7314/APJCP.2013.14.1.457
  14. Xu WP, Shen E, Bai WK, et al (2014). Enhanced antitumor effects of low-frequency ultrasound and microbubbles in combination with simvastatin by downregulating caveolin-1 in prostatic DU145 cells. Oncol Lett, 7, 2142-8.
  15. Zhang K, Zhang X (2014). Treatment strategies for locally advanced prostate cancer. Chin Med J (Engl), 127, 957-60.
  16. Hu Z-H, Lin Y-W, Xu X, et al (2013). Genetic polymorphisms of glutathione s-transferase m1 and prostate cancer risk in Asians: a meta-analysis of 18 studies. Asian Pac J Cancer Prev, 14, 393-8. https://doi.org/10.7314/APJCP.2013.14.1.393

Cited by

  1. Characterization of long non-coding RNA expression profiles in lymph node metastasis of early-stage cervical cancer vol.35, pp.6, 2016, https://doi.org/10.3892/or.2016.4715
  2. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence vol.75, pp.15, 2015, https://doi.org/10.1002/pros.23052
  3. Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2 vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5070
  4. Prostate cancer downregulated SIRP-α modulates apoptosis and proliferation through p38-MAPK/NF-κB/COX-2 signaling vol.13, pp.6, 2017, https://doi.org/10.3892/ol.2017.6070